Jiang Haiyan, Dai Min, Wu Yao, Dong Yansong, Qi Lei, Xi Qinghua, Liang Guiwen
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, China.
Department of Emergency Medicine, Affiliated Hospital of Nantong University, Nantong, China.
Transl Cancer Res. 2020 Jul;9(7):4433-4443. doi: 10.21037/tcr-20-2435.
Despite a large amount of evidence showing the involvement of microRNA-132 (miR-132) in the occurrence and prognosis of many different types of cancer, the role of miR-132 in ovarian cancer and its potential molecular mechanism have yet to be fully explained.
We studied the biological function and molecular mechanism of miR-132 in ovarian cancer cell lines and clinical tissue samples using quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot, Luciferase reporter assay, CCK8 test, colony formation test, and scratch and Transwell assays.
The expression level of miR-132 was significantly reduced in ovarian cancer cell lines and clinical tissue samples. When the level of miR-132 was increased, the proliferation, colony-forming, migration, and invasion abilities of ovarian cancer cells were significantly inhibited. We found that miR-132 inhibits the expression of transcription factor CT10 Oncogenic Gene Homologue II (CRKII) through specific targeting of mRNA 3'-UTR. We also observed a significant increase in CRKII expression in ovarian cancer. Notably, CRKII expression was negatively correlated with miR-132 expression in clinical ovarian cancer tissue. Down-regulation of CRKII had a similar inhibitory effect on miR-132 overexpression in ovarian cancer cells, while excessive expression of CRKII reversed the inhibitory effect mediated by the excessive expression of miR-132.
miR-132 inhibits the proliferation, invasion, and migration abilities of ovarian cancer cells through targeting CRKII.
尽管大量证据表明微小RNA-132(miR-132)参与多种不同类型癌症的发生和预后,但miR-132在卵巢癌中的作用及其潜在分子机制尚未完全阐明。
我们使用定量逆转录聚合酶链反应(qRT-PCR)、蛋白质免疫印迹法、荧光素酶报告基因检测、CCK8检测、集落形成检测以及划痕和Transwell检测,研究miR-132在卵巢癌细胞系和临床组织样本中的生物学功能和分子机制。
miR-132在卵巢癌细胞系和临床组织样本中的表达水平显著降低。当miR-132水平升高时,卵巢癌细胞的增殖、集落形成、迁移和侵袭能力受到显著抑制。我们发现miR-132通过特异性靶向mRNA 3'-UTR抑制转录因子CT10致癌基因同源物II(CRKII)的表达。我们还观察到卵巢癌中CRKII表达显著增加。值得注意的是,在临床卵巢癌组织中,CRKII表达与miR-132表达呈负相关。CRKII的下调对卵巢癌细胞中miR-132过表达具有类似的抑制作用,而CRKII的过表达则逆转了miR-132过表达介导的抑制作用。
miR-132通过靶向CRKII抑制卵巢癌细胞的增殖、侵袭和迁移能力。